Segments - Esoteric Testing Market by Type (Oncology Testing, Genetic Testing, Immunology Testing, Infectious Diseases Testing, Endocrinology Testing, Toxicology Testing, Neurology Testing, and Others), Technology (Enzyme-linked Immunosorbent Assay, Mass Spectrometry, DNA Sequencing, Chemiluminescence Immunoassay, Real Time Polymerase Chain Reaction, Flow Cytometry, and Others), End-user (Independent and Reference Laboratories and Hospital-based Laboratories), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2024–2032
The global esoteric testing market size was USD 18.7 Billion in 2023 and is projected to reach USD 58.45 Billion by 2032, expanding at a CAGR of 13.5% during 2024–2032. The market growth is attributed to the growing awareness of esoteric testing.
Increasing demand for personalized medicine is boosting the esoteric testing market in the coming years. Personalized medicine relies heavily on advanced diagnostic techniques to tailor treatments to individual patients based on their genetic makeup and disease characteristics. Esoteric tests offer precise insights into a patient's unique biology, enabling healthcare providers to make informed treatment decisions. Moreover, the surging adoption of novel personalized medicine approaches approved by governing agencies further fueling the demand for esoteric testing solutions.
According to the report published on April 17, 2024, personalized medicines comprised 21% of the total FDA-approved new molecular entities in 2014. By 2023, this proportion had risen to 38%.
The use of artificial intelligence is likely to boost the esoteric testing market. AI-powered predictive analytics identify patterns and trends in patient data, which facilitates early disease detection and personalized treatment strategies. Furthermore, AI-enabled robotic automation enhances laboratory operations, from sample processing to result reporting, ensuring precision and reliability.
Growing prevalence of chronic diseases is anticipated to boost the market during the forecast period. Chronic diseases, such as cancer, cardiovascular disorders, and diabetes impose a burden on healthcare systems worldwide. Esoteric tests detect and monitor chronic conditions, enabling timely intervention and personalized treatment strategies. Furthermore, these platforms offer rapid and sensitive detection methods, which further boosts their demand in the coming years.
As per the report published on December 18, 2023, around 60% of adults in the US live with chronic conditions like cancer, heart disease, or diabetes.
High cost associated with esoteric testing procedures is expected to hamper the market. These tests often involve sophisticated technologies and specialized reagents, which results in elevated testing costs as compared to conventional diagnostic tests. Moreover, the limited awareness and understanding of esoteric testing among healthcare professionals and patients further hinder the market.
Growing investment in R&D activities is likely to create immense opportunities for the players competing in the market. Pharmaceutical companies are focusing on addressing unmet clinical needs and expanding the utility of esoteric tests across diverse medical applications. Furthermore, increasing focus on early disease detection and preventive healthcare initiatives fuels the demand for esoteric testing services.
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.
Attributes |
Details |
Report Title |
Esoteric Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2023 |
Historic Data |
2017 -2022 |
Forecast Period |
2024–2032 |
Segmentation |
Type (Oncology Testing, Genetic Testing, Immunology Testing, Infectious Diseases Testing, Endocrinology testing, Toxicology Testing, Neurology Testing, and Others), Technology (Enzyme-linked Immunosorbent Assay, Mass Spectrometry, DNA Sequencing, Chemiluminescence Immunoassay, Real Time Polymerase Chain Reaction, Flow Cytometry, and Others), and End-user (Independent and Reference Laboratories and Hospital-based Laboratories) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
Key Players Covered in the Report |
ARUP Laboratories; Athena Esoterix, LLC; Bruker; F. Hoffmann-La Roche Ltd; Laboratory Corporation of America® Holdings; Mayo Foundation for Medical Education and Research (MFMER); Quest Diagnostics; and Sonic Healthcare Limited |
In terms of region, the global esoteric testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023, due to the presence of strong healthcare infrastructure and advanced diagnostic capabilities, make it conducive to the adoption of esoteric testing services. Additionally, favorable reimbursement policies facilitate the widespread availability and accessibility of esoteric tests in this region.
The market in Asia Pacific is projected to grow at a significant pace in the years to come, owing to the rising healthcare expenditure in countries, including China, India, and Japan creates a high demand for advanced diagnostic solutions, including esoteric tests. Moreover, the growing burden of chronic and infectious diseases in the region further fuels the demand for esoteric testing services.
Based on type, the esoteric testing market is divided into oncology testing, genetic testing, immunology testing, infectious diseases testing, endocrinology testing, toxicology testing, neurology testing, and others. The oncology segment is expected to expand at a significant pace in the coming years, increasing incidence of cancer globally.
Esoteric tests help in identifying actionable mutations, predicting treatment responses, and monitoring disease progression in cancer patients. For instance, according to the report published by the WHO on February 3, 2022, cancer is a leading cause of death globally, resulting in nearly 10 million deaths in 2020. Moreover, advancements in genomic technologies, such as next-generation sequencing (NGS) and liquid biopsy enable personalized medicine approaches. These all factors contribute to boosting the market.
On the basis of technology, the global market is segregated into enzyme-linked immunosorbent assay, mass spectrometry, DNA sequencing, chemiluminescence immunoassay, real time polymerase chain reaction, flow cytometry, and others. The mass spectrometry segment held largest market share in 2023, as they offer high sensitivity, specificity, and multiplexing capabilities, making them well-suited for a wide range of esoteric testing applications. Additionally, the expanding applications of mass spectrometry in biomarker discovery, therapeutic drug monitoring, and toxicology testing further boost their demand.
The DNA sequencing segment is anticipated to expand at a substantial CAGR during the forecast period, owing to the growing demand for affordable DNA sequencing-based esoteric tests. Moreover, expanding applications of DNA sequencing in epigenomics, transcriptomics, and metagenomics further fuels the segment in the coming years.
Based on end-user, the esoteric testing market is segmented into independent and reference laboratories and hospital-based laboratories. The independent and reference laboratories segment is projected to register a robust growth during the assessment years.
Independent laboratories offer greater flexibility, scalability, and specialization in esoteric testing services and catering to the diverse needs of healthcare settings. Moreover, independent laboratories often leverage advanced technologies, automation, and expertise to deliver high-quality esoteric testing solutions with rapid turnaround times and superior accuracy. These factors are fueling the segment during the forecast period.
The esoteric testing market has been segmented on the basis of
Key players competing in the global esoteric testing market are ARUP Laboratories; Athena Esoterix, LLC; Bruker; F. Hoffmann-La Roche Ltd; Laboratory Corporation of America Holdings; Mayo Foundation for Medical Education and Research (MFMER); Quest Diagnostics; and Sonic Healthcare Limited.
These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base worldwide. For instance,
On May 2, 2024, Bruker, a biotechnology solutions provider, announced the acquisition of ELITechGroup for EUR 870 million, excluding the carved-out ELITech clinical chemistry business. This acquisition enhances Bruker's portfolio in biomedical systems/specialty IVD, molecular diagnostics (MDx), and microbiology.